Lupus Ventures Takes Stake in Glycostem

December 2017 - Netherlands-based Lupus Ventures has invested €3 million in Glycostem, furthering the company’s expansion and ongoing technological development. Glycostem will channel this funding primarily to production optimisation and automation.

Orphan-Drug Designation request of NK Cell Product oNKord® granted by FDA

April 20, 2016 - On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)

Glycostem's NK Cell Product oNKord® received Orphan drug designation for AML

18 November 2014, EMA/COMP/641491/2014
During their plenary meeting on 11-13 November 2014 the Committee for Orphan Medicinal Products (COMP) has adopted at the first discussion a positive opinion recommending Glycostem's NK Cell Product* for designation as orphan medicinal product to the European Commission (EC).